ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
撤回
1
100.0%
暂无批准数据
- A comprehensive pipeline analysis reveals 12+ companies developing 15+ novel therapies for focal segmental glomerulosclerosis (FSGS), a rare kidney disorder with limited treatment options. - Travere Therapeutics' sparsentan (Filspari) has received FDA acceptance for supplemental approval following successful DUPLEX trial results showing sustained proteinuria reduction in FSGS patients. - Survey data from 102 U.S. nephrologists indicates only half of FSGS patients are considered optimally managed, driving strong physician interest in emerging therapies targeting APOL1-mediated disease. - The next 12-18 months are expected to redefine FSGS treatment standards, with multiple agents advancing toward regulatory milestones and potential FDA decisions in early 2026.
- The FDA has authorized emergency compassionate use of ZyVersa Therapeutics' VAR 200 for a patient with ApoCII amyloidosis, an ultra-rare kidney disease with no effective treatment options. - VAR 200, currently in Phase 2a trials for diabetic kidney disease, targets lipid accumulation in kidneys and was selected based on evidence of lipotoxic glomerular injury in the patient's kidney biopsy. - The treatment will be administered at the University of Miami under Dr. Alessia Fornoni's care, following the protocol of the ongoing diabetic kidney disease clinical trial. - This compassionate use case represents a precision medicine approach to match patients with specific molecular signatures to targeted therapies for rare diseases.
- ZyVersa Therapeutics has activated its first clinical site in San Antonio, Texas, to begin patient recruitment for a Phase 2a trial of VAR 200, a potential first-in-class treatment targeting renal lipotoxicity in diabetic kidney disease. - VAR 200 addresses an unmet medical need by targeting excess cholesterol and lipid accumulation in kidney glomeruli, a neglected pathogenic pathway with no currently available therapies. - The 16-week open-label study will evaluate VAR 200's efficacy and safety in patients with type 2 diabetes and diabetic kidney disease, with preliminary data expected in H2-2025. - Preclinical studies demonstrated VAR 200's ability to reduce cholesterol and lipid levels, protect against renal injury and fibrosis, and improve proteinuria across multiple kidney disease models.
- New research validates that microglia-driven inflammation plays a pivotal role in Parkinson's disease progression, with studies showing IC 100 can block NLRP1 inflammasome activation and reduce toxic alpha-synuclein accumulation. - ZyVersa Therapeutics' Inflammasome ASC Inhibitor IC 100 demonstrates potential as a disease-modifying therapy by targeting both inflammasome formation and protein aggregation, addressing underlying disease mechanisms rather than just symptoms. - The findings, supported by the Michael J. Fox Foundation, could represent a significant advancement for the 10 million Parkinson's patients worldwide, with ZyVersa preparing to initiate proof-of-concept studies in animal models later this year.
- ZyVersa Therapeutics' CEO, Stephen C. Glover, will attend the JPM Healthcare Conference in January 2025 to discuss the company's pipeline. - VAR 200, a Cholesterol Efflux Mediator, is set to begin Phase 2a clinical trials for diabetic kidney disease in Q1 2025. - IC 100, an Inflammasome ASC Inhibitor, is being developed for obesity with metabolic complications, including cardiovascular disease. - ZyVersa is focusing on first-in-class drugs for inflammatory and renal diseases with significant unmet medical needs.
- ZyVersa Therapeutics highlights data showing inflammasome inhibition protects pancreatic islet beta cells, preventing obesity progression to type 2 diabetes. - Research indicates inflammasome-driven inflammation severely damages pancreatic islets, leading to cell loss and metabolic dysfunction. - ZyVersa's Inflammasome ASC Inhibitor IC 100, an add-on to incretin therapy, showed improved metabolic status in obesity mouse models. - Phase 1 trials for IC 100 are planned for mid-2025, marking a step forward in obesity and related comorbidities treatment.
